Essex Woodlands seeks $750 mln for ninth fund


healthcare investing

Essex Woodlands Health Ventures is out fundraising for its latest pool, sources said.

The healthcare growth equity firm is seeking $750 million for its ninth fund, one placement source said. That is less than the $900 million raised by Essex’s prior pool, Essex Woodlands Health Ventures Fund VIII, in 2009.

Fund VIII was generating a 6.2% IRR as of March 31, according to the Oregon Public Employees Retirement Fund.

Results aren’t better for Essex’s seventh fund, which raised $600 million in 2006. Essex Fund VII is producing a meager 1.1% IRR, Oregon data shows.

Officials for Essex declined comment.

Founded in 1985, Essex makes mostly growth equity investments with a minority of deals focused on venture capital, according to the firm’s website. The firm targets pharmaceuticals, biotechnology, medical devices, healthcare services and healthcare IT. Essex can provide up to $100 million for a growth equity deal, but investments typically range between $20 million to $60 million equity.

Essex, which has offices in Palo Alto, Calif., Houston, Shanghai, New York and London, doesn’t appear to have done a deal lately, based on public information. In May 2012, the firm launched Bioventus, which was Smith & Nephew’s former Biologics Division/Clinical Therapies business. Silver Lake Sumeru, along with Essex Woodlands, acquired Medseek, a provider of online strategic patient engage and analytics software, also in 2012. Essex led the $40 million funding round for IntegenX in December 2011. In September 2011, Essex also led the $22 million funding round for BreatheAmerica.

Photo courtesy of Shutterstock

 

Connect with your peers at the 9th Annual PartnerConnect West in San Francisco on September 27–28.

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.